Mark M. Zalupski, MD, professor of medicine at the University of Michigan School of Medicine, discusses the clinical implications of the phase III KEYNOTE-061 trial in gastric cancer.
Mark M. Zalupski, MD
Advertisement
Articles by Mark M. Zalupski, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
From Toilet Cleaner to Thoracic Oncologist and Patient: How Ross Camidge Built a Life Worth Loving
3
Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ASCO 2026
4
The OncFive: Top Oncology Articles for the Week of 5/31
5